Shenzhen Salubris Pharmaceuticals (SHE:002294) received approval from China's National Medical Products Administration for the clinical trial of its SAL0195 injection.
The drug will be tested as a treatment for elevated lipoprotein(a) levels, according to a Shenzhen bourse filing on Saturday.